Kornimate/medical-research-clean huggingface dataset:
the effect of video game exercise on dynamic balance and gait in individuals with huntington's disease

Conditions: Huntington's Disease

Summary: to examine the benefits of using a video-game, dance, dance, revolution, as an exercise modality to improve gait and balance in individuals with huntington's disease.

the primary purpose of this study was to determine the effectiveness of a therapist-guided video-game biofeedback modulated exercise (vibe) program administered via dance dance revolution to improve dynamic balance, gait and mobility in individuals with huntington's disease. secondary aims were to explore whether the vibe intervention would improve quality of life, fall risk, and neuropsychological functions. the investigators hypothesized that the video-game program would lead to greater improvements in walking, dynamic balance, quality of life, fall risk, and neuropsychological function than a control handheld video game program. since motivation is essential to the long-term maintenance of an exercise program the investigators were also interested in finding out how successful people with huntington's disease were at playing dance dance revolution, what their perceptions were of playing the game, and whether they thought that it was beneficial

Eligibility criteria:
inclusion criteria: * adults 18 - 79 with a diagnosis of huntington's disease exclusion criteria: * cannot walk 10 feet without assistance, any other neurologic condition

Keywords: huntington's disease gait exercise balance video game
prostate cancer burden and heterogeneity evaluation towards liquid biopsy: a correlation study to 18fdcfpyl pet and patients outcome

Conditions: Prostate Cancer

Summary: this is a prospective, monocentric, proof of concept study aims to identify in prostate cancer patients, a potential relationship between ctc-psma positivity and 18f-pet-psma results as well as patient outcome. patients with 18f-pet-psma indication will perform imaging extension work-up as part of current practice. if they agree to participate in the study, a blood sample will be performed prior to the 18f-pet-psma standard imaging (t1). in order to evaluate the potential relationship between ctc-psma and 18f-pet-psma imaging, the study will be presented to all patients seen in consultation for an extension workup for prostate cancer. this will allow to analyze the results in patients with different level of tumor burden afterward to define the following three groups based on imaging results: group 1 : no tumor volume negative 18f-pet-psma (patients without uptake lesion) group 2 : low or medium tumor volume positive 18f-pet-psma (patients with an uptake in prostate bed or with an oligo-metastatic extension (number of lesions \< 6)) group 3 : high tumor volume positive 18f-pet-psma (patients with a polymetastastatic extension (number of lesions ≥ 6)). in each of these groups, the rate of patients with positive psma ctc will be analyzed (i.e. patient having at least one ctc-psma positive). for patients with an indication of treatment by 177lupsma-617 (pluvicto®) according to standard practices, additional blood samples will also be collected at the following time points: 2nd cycle (t2) and 4th cycle of treatment (t3), just before injection. for these patients, data will be collected up to 6 months after the last treatment injection (clinical and biological data; results of tumor assessments based on 18f-pet-psma imaging).


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. histologically confirmed adenocarcinoma of the prostate 3. indication for 18f-pet-psma imaging 4. signed written informed consent 5. patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol 6. patient affiliated to a social health insurance in france. exclusion criteria: 1. patients with a contraindication to 18f-pet-psma 2. patient with an established neuro endocrine prostate cancer 3. concurrent malignancy known to express a significant amount of psma (renal cancer, salivary gland tumors) 4. any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure 5. patient who has forfeited his freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Keywords: prostate cancer 18f-pet-psma circulating tumor cells liquid biopsy
a dose-response of the effects of exendin-9,39 on gi symptoms and food intake

Conditions: Obesity; Diabetes; Roux-en-Y Gastric Bypass

Summary: exendin-(9,39) has been shown to have effects on beta-cell function, and after gastric bypass, to accelerate gastrointestinal transit. - infused at rates of 300pmol/kg/min. given that gastrointestinal transit is typically delayed by glucagon-like peptide-1 (glp-1) and also that this hormone causes decreased food intake through increased satiation, it is reasonable to expect an effect of exendin-9,39 on appetite. this may help explain the effects of gastric bypass on food intake. to examine the effect of exendin on food intake we propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion. we will examine the presence of gastrointestinal symptoms as well as food intake in the immediate aftermath of a test meal and the subsequent hours.


Eligibility criteria:
inclusion criteria: * subjects who have undergone roux en-y gastric bypass at least 6 months prior to enrollment in the study. * subjects without active systemic illness. exclusion criteria: * subjects \<20 years of age will not be studied to minimize the possibility of type 1 diabetes. * subjects \>70 years of age will not be studied to minimize the potential confounding effects of age on glucose tolerance.
clinical impact of hypothermic machine perfusion in renal transplant recipients

Conditions: Delayed Function of Renal Transplant

Summary: this is a multi-centers prospective, randomized, controlled trial. this trial will investigate the clinical outcome of kidney transplant recipients whose kidneys are under two different forms of organ preservation--hypothermic machine perfusion vs. static cold storage. factors during the machine perfusion, such as the pressure, flow rate, and resistance index will also be investigated.

in this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. all 400 patients will be followed for 1 year. the primary endpoint is delayed graft function (requiring dialysis in the first week after transplantation) and duration of delayed graft function. the second endpoints: gfr at week 1, month3, month6 and month 12 post-transplant.

Eligibility criteria:
inclusion criteria: * donor 1. comply with the national dcd（donor after citizen death) guideline 2. no high risk activities: such as history of drug abuse, history of intravenous drug use and risky sexual behavior 3. no malignant melanoma, metastatic cancer, or incurable cancer; some of the early stages of cancer after a successful treatment can also be considered 4. no active, untreated systemic bacterial, viral or fungal infection; 5. patients definitely identified 6. mechanical perfusion ri (resistance index ) \[0.18, 0.50\] recipient: 1. age\> = 16 years old, male or female 2. bmi\<28 3. first renal transplantation 4. not in pregnancy or lactation, pregnancy test was negative, and promise not to be pregnant during treatment. 5. before the clinical trial, patient sign informed consent voluntarily exclusion criteria: * donor 1. older than 50 years old 2. serum hbv (hepatitis b virus), hcv (hepatitis c virus), hiv positive 3. donor kidney cold storage time over 30 hours 4. warm ischemia time over 20 minutes 5. other reagents are added perfusion for regulation of donor renal function recipient: 1. double organ or multi-organ transplant 2. blood type-incompatible 3. patients with other malignant diseases

Keywords: hypothermic machine perfusion kidney transplantation delayed graft function perfusion pressure
postoperative arrhythmia and preoperative cardiac function

Conditions: The Cardiac Function

Summary: this study aims to investigate the association between echocardiographic parameters-including preoperative cardiac echo, as well as postoperative follow-up echocardiography and other associated parameters-and the risk factors related to postoperative arrhythmia

postoperative atrial fibrillation (poaf), defined as newly onset atrial fibrillation occurring during hospitalization, is a common complication following cardiac surgery, affecting approximately 20-30% of patients. studies have shown that patients who develop poaf experience longer hospital stays, incur higher medical costs, and have increased rates of stroke- and heart failure-related complications, as well as higher risks of readmission and mortality. poaf is generally believed to result from acute perioperative triggers acting on preexisting structural abnormalities of the atria or ventricles. however, the echocardiographic predictors of poaf remain poorly understood. while previous studies have examined the association between preoperative transthoracic echocardiography (tte)-assessed left atrial and left ventricular function and the development of poaf, the detailed relationship between intraoperative transesophageal echocardiography (tee)-assessed atrial and ventricular function, its intraoperative changes, and poaf remains insufficiently explored. this study aims to investigate the association between echocardiographic parameters-including preoperative tte and tee, as well as postoperative follow-up parameters-and the risk factors related to poaf.

Eligibility criteria:
inclusion criteria: * patients receiving cardiac surgery exclusion criteria: * preoperative arrhythmia

Keywords: cardiac echo cardiac surgery
randomized controlled trial of immuknow in liver transplantation

Conditions: Liver Disease

Summary: immuknow detects cell-mediated immunity in solid-organ transplant recipients undergoing immunosuppressive therapy. increasing immuknow values indicate a decrease of immunosuppression and decreasing immuknow values suggest an increase of immunosuppression. the test measures the amount of atp produced in cd4+ lymphocytes as a biomarker of lymphocyte activation. this study uses the immuknow assay to proactively adjust immunosuppressive therapy in adult liver transplant recipients to reduce the risk of adverse events

we performed a randomized prospective interventional trial where the interventional group had immunosuppression modified according to immuknow values. immunosuppression was decreased by 25% if immuknow values were less than 130 ng/ml atp. similarly, immunosuppression was increased by 25% if immuknow values were greater than 450 ng/ml atp. immunosuppression of the control group was managed by the standard of care at our institution. immuknow was performed before liver transplant, after surgery and at each clinic visit with the approximate schedule: day 1; weekly, weeks 1-4; week 6; week 8; monthly, months 3-6; and months 9 and 12. immuknow testing was repeated within 7 days of a suspected/confirmed rejection or infection and again within 1 week of resolution.

Eligibility criteria:
inclusion criteria: * consecutive adult liver transplant recipients at our center; * patients not entered into other studies; * provided consent. exclusion criteria: * available follow-up; * consent removed.

Keywords: immune monitoring immune cell function immuknow randomized controlled trial immunosuppression management infection rejection liver transplantation cylex
benefits of exercise training in head and neck cancer patients undergoing organ-preserving definitive therapy

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: the purpose of this study is to evaluate the potential benefit of an individualized resistance exercise-training program during radiotherapy for patients with locally advanced head and neck cancer.

patients with locally advanced head and neck cancer are treated with radiation therapy (with/without chemotherapy) to avoid large surgical procedures. however, definitive radiation treatments can cause side effects (like mouth sores, difficulty swallowing) that often cause weight loss. it has been shown that a significant percentage of the weight loss is due to loss of muscle mass. resistance exercise training works to increase muscle strength and endurance by doing repetitive exercises with weights, weight machines, or resistance bands.

Eligibility criteria:
inclusion criteria: * patients with american joint committee on cancer (ajcc) stage ii-iv head and neck squamous cell carcinoma who are beginning first-line non-surgical treatment with radiotherapy (with or without chemotherapy or targeted agents), and who are capable of understanding and adhering to the protocol requirements. * patients must be willing to comply with the study procedures and visits exclusion criteria: * active cardiopulmonary disease * substantial dementia (based on folstein mini mental state examination \<24 out of 30) * acute medical conditions, such as acute flare-up of joint condition or infection * participants must not be actively receiving physical therapy, at time of enrollment, or actively exercising 2 or more hours a day, with the intent to continue that regimen * patients refusing a percutaneous endoscopic gastrotomy (peg) tube needed for nutrition, as determined necessary by treating physician * patients are actively being treated for another cancer at the time of enrollment.
sex hormones and orthostatic tolerance

Conditions: Orthostatic Intolerance

Summary: this study is designed to determine the causes of "orthostatic intolerance" which occurs more commonly in women than in men. orthostatic tolerance is the ability to remain standing up right for long periods of time, or to avoid dizziness when moving to standing from a seated or lying position.

in this study we are interested in determining the impact of female reproductive hormones (estrogen and progesterone) on orthostatic tolerance (described above) so we administer these hormones to participants. we also test participants' orthostatic tolerance in our laboratory and use this information to place subjects into groups.

Eligibility criteria:
inclusion criteria: * healthy, english-speaking non-smoking women age 18- 34 with regular menses exclusion criteria: * gynecologic: 1. current or past estrogen-dependent neoplasia, 2. unexplained vaginal bleeding, 3. history of uterine fibroids, 4. current pregnancy, 5. known or suspected breast or uterine cancer, 6. partial or complete hysterectomy * cardiac: 1. myocardial infarction, ventricle tachycardia or fibrillation, 2. angina, 3. valvular disease, 4. congestive heart failure, orthopnea, paroxysmal nocturnal dyspnea, 5. current arrhythmias, 6. prosthetic valves * pulmonary: 1. current cigarette smokers, or pipe or cigar smokers, 2. chronic obstructive pulmonary disease, 3. adult asthma, 4. dyspnea on exertion, 5. current bronchitis, pneumonia, or tuberculosis, 6. lung carcinoma, 7. pulmonary embolus, recent * vascular: 1. claudication or history of peripheral vascular disease, 2. abdominal or thoracic aortic aneurysm, or repair of same, 3. cerebral aneurysm, vascular malformations, 4. hypertension, systolic or diastolic, or strong family history of hypertension * gastrointestinal: 1. gi malignancy, 2. hepatitis, current, 3. splenomegaly from any cause, 4. cholecystitis, 5. current diverticulosis or diverticulitis, inflammatory bowel disease, ulcerative colitis, crohn's disease, 6. previous gastrointestinal surgery * infectious disease: any intercurrent infection * hematologic/oncologic: 1. receiving chemotherapy or radiation therapy, 2. any metastatic malignancy, 3. anemia (hematocrit \< 35), 4. thrombocytopenia or thrombocytosis, 5. neutropenia, 6. hematologic malignancy, 7. bleeding dyscrasia * neurologic: 1. history of cerebral vascular accident with any neurologic sequels, 2. uncontrolled seizures (e.g. more than 1 seizure/year), 3. transient ischemic attacks, 4. dementia, 5. neurologic conditions producing dyscoordination, peripheral neuropathy, or myopathy, 6. severe migraine headaches * endocrine: 1. diabetes mellitus, 2. any untreated endocrinopathy * renal: 1. chronic renal disease, 2. any history of renal disease or impairment, 3. current urinary tract infection * musculoskeletal: 1. inflammatory arthritis history (e.g., rheumatoid, psoriatic, reiters), 2. any history of pathologic fractures, including vertebral compression fractures * pharmacologic: 1. any illegal drug use, 2. alcohol use greater than an average of 4 oz/day over 30 days, 3. coumadin or heparin use, 4. current systemic antifungal use
electrotherapy combined with neck exercises for non-specific neck pain

Conditions: Chronic Pain

Summary: objectives: the objective of this study is to compare the effectiveness of telerehabilitation versus a face-to-face program in the therapeutic approach to non-specific neck pain through exercise and analgesic electrotherapy. methods: randomized clinical trial on 100 participants with nonspecific neck pain who will be randomized into two groups to receive analgesic electrotherapy combined with a cervical exercise program through telemedicine or face to face. a total of 20 sessions will be applied over 8 weeks. demographic and clinical data, disability, pain intensity, kinesiophobia, isometric spinal muscle strength, quality of life, and cervical mobility will be collected. assessments will be performed at the beginning of the study (baseline), at 8 weeks (post-treatment) and 6 months after the end of the intervention (follow-up).

introduction: neck pain is a common problem in the working-age population, with a high recurrence rate and one of the highest health costs globally. exercise is considered one of the keys in the management of this pathology, and electrotherapy is consolidated as a safe and proven analgesic measure. telemedicine facilitates access to health care by eliminating geographical barriers and reducing costs, allowing consultations from any location and favoring the patient's work-life balance. the widespread availability of smartphones, tablets and computers makes telerehabilitation more accessible than ever. objectives: the objective of this study is to compare the effectiveness of telerehabilitation versus a face-to-face program in the therapeutic approach to non-specific neck pain through exercise and analgesic electrotherapy. methods: randomized clinical trial with 100 participants with nonspecific neck pain who will be randomized into two groups to receive analgesic electrotherapy combined with a cervical exercise program through telemedicine or face to face. a total of 20 sessions will be applied over 8 weeks. demographic and clinical data, disability, pain intensity, kinesiophobia, isometric spinal muscle strength, quality of life, and cervical mobility will be collected. assessments will be performed at the beginning of the study (baseline), at 8 weeks (post-treatment) and 6 months after the end of the intervention (follow-up).

Eligibility criteria:
inclusion criteria: * male and female patients between the ages of 30 and 65, with a medical diagnosis of cervical pain of non-specific origin, * acceptance and signature of informed consent for voluntary participation in the research study. * not receiving physical therapy. * chronic cervical pain lasting 3 months or more and not receiving any other type of physiotherapy treatment. exclusion criteria: * patients undergoing rehabilitation treatment for pathologies of cervical origin. * patients have osteosynthesis material at the cervical level and/or cardiac complications, epilepsy or tumors. * patients who have undergone radiotherapy in the last 6 months.
a phase 2 clinical trial of vla1553 in healthy children aged 1 to 11 years

Conditions: Chikungunya Virus Infection

Summary: this is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of vla1553, half dose formulation of vla1553 and control. at least 300 male and female healthy children aged 1 to 11 years will be enrolled and the overall distribution of participants will be 2:2:1 to the two vla1553 dose groups (n=120 each) or control (n=60).

this is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of vla1553, half dose formulation of vla1553 and control (nimenrix, a tetravalent meningococcal vaccine - men acwy). at least 300 male and female healthy children aged 1 to 11 years will be enrolled and the overall distribution of participants will be 2:2:1 to the two vla1553 dose groups (n=120 each) or control (nimenrix) (n=60). as a safety precaution measure, the first 30 sentinel participants will be enrolled into the trial in an open-label fashion according to an age step down scheme. after sentinel analysis, participants will be enrolled in a blinded, randomized manner into three trial arms. within each treatment arm participants will be stratified into three age strata: stratum a: 7 to 11 years -children from their 7th birthday until the day before their 12th birthday. stratum b: 3 to 6 years - children from their 3rd birthday until the day before their 7th birthday. stratum c: 1 to 2 years - children from their 1st birthday until the day before their 3rd birthday. age strata for the vla1553 treatment arms are targeted to be equal in size, i.e., approximately 40 per age stratum.

Eligibility criteria:
inclusion criteria: 1. male or female healthy children aged 7 to 11 years for stratum a, 3 to 6 years for stratum b and 1 to 2 years for stratum c at the time of vaccination; 2. written informed consent by the participant's parent(s)/legally acceptable representative(s) ((lar(s)), according to local requirements, and written informed assent of the participant, if applicable; exclusion criteria: 1. participant who is igm+/igg- does not qualify for participation in this trial. 2. participant is taking medication or other treatment for unresolved symptoms attributed to a previous chikv infection; or has participated in a clinical trial involving an investigational chikv vaccine; 3. participant has an acute or recent infection (and who is not symptom-free in the week prior to the screening visit (visit 0)
effect of paracetamol on the common cold

Conditions: Common Cold

Summary: the aim of this study is to subjectively assess symptoms in subjects suffering from the common cold following a single dose of paracetamol hot drink compared to paracetamol tablet


Eligibility criteria:
inclusion criteria: * symptoms of the common cold of no more than 120 hours duration * self-rating congestion of at least moderate severity * suffering from at least four symptoms of common cold or flu

Keywords: paracetamol common cold
xylitol chewing-gums: concentration in saliva and antibacterial effect

Conditions: Dental Caries; Periodontal Diseases

Summary: a double-blind cross-over in vivo study was performed to measure the salivary concentration of xylitol released from the two chewing gums containing different amount of the polyol. the study had a cross-over design: the first half of the sample used the chewing-gum with xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums. subjects were instructed to consume the products as they normally would be consumed.

x

Eligibility criteria:
inclusion criteria: * good general health, * the absence of diseases that can alter the saliva secretion rate * a stimulated saliva flow at least of 1 ml/min. exclusion criteria: -

Keywords: xylitol saliva bacteria dental plaque antimicrobial effect chewing gum